Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Expert Review of Anticancer Therapy|November 25, 2014
Afatinib and lung cancerPrantesh Jain, Rashmi Khanal, Aakanksha Sharma, et al.Frontiers in Immunology|May 7, 2026
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategiesAnirudh Rao, Christina Darwish, Kerry S Campbell, et al.Cancer Medicine|November 27, 2025
"I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous TransplantationZachary A K Frosch, Clark Meshack, Caitlin Meeker, et al.Cancer Medicine|May 16, 2026
Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active SurveillanceCarolyn Y Fang, Alexander W MacFarlane, Henry C H Fung, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin LymphomaSattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.Pageof 1